Paper39337361
The Role of Mutated Calreticulin in the Pathogenesis of BCR-ABL1-Negative Myeloproliferative Neoplasms.
Vadeikienė R and 5 others. Int J Mol Sci, 2024. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. The Role of Mutated Calreticulin in the Pathogenesis of BCR-ABL1-Negative Myeloproliferative Neoplasms. Papers, record 39337361. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39337361
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The Role of Mutated Calreticulin in the Pathogenesis of BCR-ABL1-Negative Myeloproliferative Neoplasms.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Calreticulin | Major topic |
| Fusion Proteins, bcr-abl | Major topic |
| Mutation | Major topic |
| Myeloproliferative Disorders | Major topic |
| Humans | |
| DNA Damage | |
| Oxidative Stress | |
| Phosphatidylinositol 3-Kinases | |
| Signal Transduction | |
| TOR Serine-Threonine Kinases |
Source PubMed
References93
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 17632527 | Essential role of stromally induced hedgehog signaling in B-cell malignancies. | Nat Med | 2007 | https://conductscience.org/library/papers/17632527 | PubMed |
| 2 | 24421250 | CALR mutation studies in chronic neutrophilic leukemia. | Am J Hematol | 2014 | https://conductscience.org/library/papers/24421250 | PubMed |
| 3 | 34193229 | Molecular pathogenesis of the myeloproliferative neoplasms. | J Hematol Oncol | 2021 | https://conductscience.org/library/papers/34193229 | PubMed |
| 4 | 29274272 | The role of the Hedgehog signaling pathway in cancer: A comprehensive review. | Bosn J Basic Med Sci | 2018 | https://conductscience.org/library/papers/29274272 | PubMed |
| 5 | 30754640 | mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy. | Int J Mol Sci | 2019 | https://conductscience.org/library/papers/30754640 | PubMed |
| 6 | 8329702 | Establishment and characterization of an erythropoietin-dependent subline, UT-7/Epo, derived from human leukemia cell line, UT-7. | Blood | 1993 | https://conductscience.org/library/papers/8329702 | PubMed |
| 7 | 33312103 | CALR mutations in myeloproliferative neoplasms: An unfolding story. | EXCLI J | 2020 | https://conductscience.org/library/papers/33312103 | PubMed |
| 8 | 15781101 | Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. | Lancet | 2005 | https://conductscience.org/library/papers/15781101 | PubMed |
| 9 | 24366362 | JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. | Blood | 2014 | https://conductscience.org/library/papers/24366362 | PubMed |
| 10 | 24895336 | Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations. | Haematologica | 2014 | https://conductscience.org/library/papers/24895336 | PubMed |
| 11 | 25691811 | Hedgehog signaling in cancer stem cells: a focus on hematological cancers. | Stem Cells Cloning | 2015 | https://conductscience.org/library/papers/25691811 | PubMed |
| 12 | 36611979 | Transcriptomic Analysis Reveals JAK2/MPL-Independent Effects of Calreticulin Mutations in a C. elegans Model. | Cells | 2023 | https://conductscience.org/library/papers/36611979 | PubMed |
| 13 | 25641433 | Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis. | Leuk Lymphoma | 2015 | https://conductscience.org/library/papers/25641433 | PubMed |
| 14 | 15793561 | A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. | Nature | 2005 | https://conductscience.org/library/papers/15793561 | PubMed |
| 15 | 15482598 | Activation of the hedgehog pathway in advanced prostate cancer. | Mol Cancer | 2004 | https://conductscience.org/library/papers/15482598 | PubMed |
| 16 | 34645293 | Environmental Factors, Lifestyle Risk Factors, and Host Characteristics Associated With Philadelphia Negative Myeloproliferative Neoplasm: A Systematic Review. | Cancer Control | 2021 | https://conductscience.org/library/papers/34645293 | PubMed |
| 17 | 29426921 | The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. | Blood Cancer J | 2018 | https://conductscience.org/library/papers/29426921 | PubMed |
| 18 | 25918716 | Functional roles of calreticulin in cancer biology. | Biomed Res Int | 2015 | https://conductscience.org/library/papers/25918716 | PubMed |
| 19 | 26538833 | The Role of Reactive Oxygen Species in Myelofibrosis and Related Neoplasms. | Mediators Inflamm | 2015 | https://conductscience.org/library/papers/26538833 | PubMed |
| 20 | 21300928 | Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. | J Clin Oncol | 2011 | https://conductscience.org/library/papers/21300928 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42131291 | CDK6 inactivation counteracts CALR-mutant-induced MPN evolution and sensitizes MPN stem cells to interferon-α treatment. | Hemasphere | 2026 | https://conductscience.org/library/papers/42131291 | PubMed |
| 40105884 | Adefovir anticancer potential: Network pharmacology, anti-proliferative and apoptotic effects in HeLa cells. | Biomol Biomed | 2025 | https://conductscience.org/library/papers/40105884 | PubMed |
| 39519157 | Myeloproliferative Neoplasm-like Mutations of Calreticulin Induce Phenotypes Associated with Calreticulin Dysfunction in C. elegans. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39519157 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AKT1 | 207 | PubTator's text mining | https://conductscience.org/library/genes/207 | NCBI Gene |
| CALR | 811 | PubTator's text mining | https://conductscience.org/library/genes/811 | NCBI Gene |
| MPL | 4352 | PubTator's text mining | https://conductscience.org/library/genes/4352 | NCBI Gene |
| MTOR | 2475 | PubTator's text mining | https://conductscience.org/library/genes/2475 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39337361
GET https://conductscience.org/api/papers/v1/39337361/references?page=2